{"organizations": [], "uuid": "76647a1731c50b7d529f13f423c4a87f5e435942", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/01/26/business-wire-immunogen-announces-conference-call-to-discuss-its-2017-operating-results.html", "country": "US", "domain_rank": 767, "title": "ImmunoGen Conference Call to Discuss Its 2017 Operating Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-26T16:00:00.000+02:00", "replies_count": 0, "uuid": "76647a1731c50b7d529f13f423c4a87f5e435942"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/01/26/business-wire-immunogen-announces-conference-call-to-discuss-its-2017-operating-results.html", "ord_in_thread": 0, "title": "ImmunoGen Conference Call to Discuss Its 2017 Operating Results", "locations": [], "entities": {"persons": [], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "waltham", "sentiment": "none"}], "organizations": [{"name": "immunogen", "sentiment": "negative"}, {"name": "inc", "sentiment": "negative"}, {"name": "company", "sentiment": "none"}, {"name": "immunogen, inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 9, 2018 to discuss its 2017 operating results. Management also will provide a brief update on the business.\nConference Call Information\nTo access the live call by phone, dial 719-325-4917; the conference ID is 5734226. The call may also be accessed through the Investors section of the Company’s website, www.immunogen.com . Following the webcast, a replay of the call will be available at the same location through February 23, 2018.\nAbout ImmunoGen, Inc.\nImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company’s lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in a Phase 1b/2 trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roche's marketed product, Kadcyla ® , and in programs in development by Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com .\nKadcyla ® is a registered trademark of Genentech, a member of the Roche Group.\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180126005034/en/\nFor Investors\nImmunoGen, Inc.\nSarah Kiely, 781-895-0600\nsarah.kiely@immunogen.com\nor\nFor Media\nImmunoGen, Inc.\nCourtney O'Konek, 781-895-0600\ncourtney.okonek@immunogen.com\nor\nRobert Stanislaro\nFTI Consulting, Inc., 212-850-5657\nrobert.stanislaro@fticonsulting.com\nSource: ImmunoGen, Inc.", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.immunogen.com&esheet=51749077&newsitemid=20180126005034&lan=en-US&anchor=www.immunogen.com&index=2&md5=cad3ee513ffc07bdb140ac91df576ba0", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.immunogen.com%2F&esheet=51749077&newsitemid=20180126005034&lan=en-US&anchor=www.immunogen.com&index=3&md5=0ab94a7027ea6541c4fa7ab7f23760b3", "http://www.businesswire.com/news/home/20180126005034/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.immunogen.com&esheet=51749077&newsitemid=20180126005034&lan=en-US&anchor=ImmunoGen%2C+Inc&index=1&md5=49bb0ec0036832bf77e459a03f320e18"], "published": "2018-01-26T16:00:00.000+02:00", "crawled": "2018-01-26T18:10:34.013+02:00", "highlightTitle": ""}